Canagliflozin
Summarized by Plex Health
Last Updated: 02 May 2022
"characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis.", by Buysman EK, Chow W, Henk HJ, Rupnow MF. Fig1: Concomitant AHA use at the time of the first canagliflozin claim (N = 4017). Concomitant AHA use was defined based on treatments the patient had available at the time of the first canagliflozin claim...
Canagliflozin is used together with diet and exercise to improve blood glucose control in adults with type 2 diabetic issues mellitus. Canagliflozin is additionally used to lower the risk of death from heart stroke, heart, or attack failure in adults with type 2 diabetic issues who also have heart problem. Canagliflozin is except dealing with type 1 diabetes. Canagliflozin can cause significant infections in the penis or vaginal canal. Canagliflozin, the active component of INVOKANA, is chemically called -1,5-anhydro-1 [3- [5-2thienyl] methyl] -4 methylphenyl] -Dglucitol hemihydrate and its molecular formula and weight are C24H25FO5S 1/2 H2O and 453. 53, respectively. The structural formula for canagliflozin is: Canagliflozin is almost insoluble in liquid media from pH 1. 1 to 12. 9 INVOKANA is supplied as film-coated tablets for oral administration, including 102 and 306 mg of canagliflozin in each tablet toughness, matching to 100 mg and 300 mg of canagliflozin, respectively. Non-active components of the core tablet are croscarmellose salt, hydroxypropyl cellulose, lactose anhydrous, magnesium stearate, and microcrystalline cellulose. The magnesium stearate is vegetable-sourced. Type 1 diabetic person patients have to use insulin shots. This medication is available only with your doctor's prescription.
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions
** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.
Sources:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9057d3b-b104-4f09-8a61-c61ef9d4a...
https://www.drugs.com/mtm/canagliflozin.html
https://www.mayoclinic.org/drugs-supplements/canagliflozin-oral-route/description/drg-2006...
PubChem - CovalentUnitCount
(Table source)| CID | MolecularFormula | MolecularWeight | CanonicalSMILES | IsomericSMILES | InChI | InChIKey | IUPACName | XLogP | ExactMass | MonoisotopicMass | TPSA | Complexity | Charge | HBondDonorCount | HBondAcceptorCount | RotatableBondCount | HeavyAtomCount | IsotopeAtomCount | AtomStereoCount | DefinedAtomStereoCount | UndefinedAtomStereoCount | BondStereoCount | DefinedBondStereoCount | UndefinedBondStereoCount | CovalentUnitCount |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24812758 | C24H25FO5S | 444.5 | CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F | CC1=C(C=C(C=C1)[[email protected]]2[[email protected]@H]([[email protected]]([[email protected]@H]([[email protected]](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F | InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1 | XTNGUQKDFGDXSJ-ZXGKGEBGSA-N | (2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol | 3.2 | 444.14067323 | 444.14067323 | 118 | 574 | 0 | 4 | 7 | 5 | 31 | 0 | 5 | 5 | 0 | 0 | 0 | 0 | 1 |
*** If you want us to remove all links leading to your domain from Plex.page and never use your website as a source of the "Online Knowledge", please contact us using a corporate email and we will remove everything in 10 business days.
Plex Page is a Biology & Health Sciences "Online Knowledge Base," where a machine summarizes all the summaries.